BR0014408A - Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos - Google Patents

Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos

Info

Publication number
BR0014408A
BR0014408A BR0014408-8A BR0014408A BR0014408A BR 0014408 A BR0014408 A BR 0014408A BR 0014408 A BR0014408 A BR 0014408A BR 0014408 A BR0014408 A BR 0014408A
Authority
BR
Brazil
Prior art keywords
antigens
cells
hsv
methods
identifying
Prior art date
Application number
BR0014408-8A
Other languages
English (en)
Inventor
David M Koelle
Hongbo Chen
Lawrence Corey
Nancy Ann Hosken
Patrick Mcgowan
Steven P Fling
Christine M Posavad
Original Assignee
Univ Washington
Corixa Corp
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Corixa Corp, Hutchinson Fred Cancer Res filed Critical Univ Washington
Publication of BR0014408A publication Critical patent/BR0014408A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"ANTìGENOS DO VìRUS DO HERPES SIMPLES IMUNOLOGICAMENTE SIGNIFICATIVOS; E MéTODOS PARA IDENTIFICAçãO E UTILIZAçãO DOS MESMOS". A invenção fornece antígenos de HSV que são úteis para a prevenção e tratamento de infecção por HSV. Descreve-se epítopos confirmados como sendo reconhecidos por células T derivadas de lesões herpéticas. As células T que têm especificidade para os antígenos da invenção demonstraram atividade citóxica contra células carregadas com epítopos de peptídeos codificados de modo viral, e em muitos casos, contra células infectadas com HSV. A identificação de antígenos imunogênicos responsáveis pela especificidade de células T fornece estratégias antivirais, terapêuticas e profiláticas, aperfeiçoadas. As composições que contêm os antígenos ou polinucleotídeos que codificam os antígenos da invenção fornecem vacinas eficazmente direcionadas para prevenção e tratamento de infecção por HSV.
BR0014408-8A 1999-09-30 2000-09-28 Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos BR0014408A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15718199P 1999-09-30 1999-09-30
US20366000P 2000-05-12 2000-05-12
US21810400P 2000-07-13 2000-07-13
PCT/US2000/026663 WO2001023414A2 (en) 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens

Publications (1)

Publication Number Publication Date
BR0014408A true BR0014408A (pt) 2002-07-02

Family

ID=27387973

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014408-8A BR0014408A (pt) 1999-09-30 2000-09-28 Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos

Country Status (16)

Country Link
US (2) US6413518B1 (pt)
EP (1) EP1222281B1 (pt)
JP (2) JP2003512305A (pt)
KR (1) KR20020048944A (pt)
CN (1) CN1376201A (pt)
AT (1) ATE345389T1 (pt)
AU (2) AU782676B2 (pt)
BR (1) BR0014408A (pt)
CA (1) CA2379623C (pt)
DE (1) DE60031874D1 (pt)
HK (1) HK1044799A1 (pt)
NO (1) NO20021479L (pt)
NZ (2) NZ531980A (pt)
PL (1) PL355265A1 (pt)
TR (1) TR200200838T2 (pt)
WO (1) WO2001023414A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2272859T3 (en) * 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
JP4519461B2 (ja) * 2001-07-31 2010-08-04 ユニヴァーシティ オブ ワシントン 免疫学的に重要な単純ヘルペスウイルス抗原およびそれを用いる方法
DK1523582T3 (da) * 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
JP2008507259A (ja) * 2004-05-24 2008-03-13 ベイラー・リサーチ・インスチチユート 免疫応答の評価方法
WO2007091064A1 (en) 2006-02-08 2007-08-16 Solexa Limited End modification to prevent over-representation of fragments
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US8609605B2 (en) 2009-03-17 2013-12-17 Cardiovax, Llc Immunomodulatory methods for treatment of atherosclerosis via inhibition of CD4+ T cell response to APOB100
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
JP2013510586A (ja) 2009-11-14 2013-03-28 チュウ、カン−ユウ アテローム性動脈硬化を治療及び／又は予防するための免疫調節方法及びシステム
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
JP6099573B2 (ja) * 2011-01-31 2017-03-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法
ES2874233T3 (es) * 2011-11-11 2021-11-04 Variation Biotechnologies Inc Composiciones y métodos para el tratamiento de citomegalovirus
EP2782597B1 (en) 2011-11-23 2022-04-13 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
CN114306596A (zh) * 2014-06-26 2022-04-12 海德堡免疫疗法有限公司 抗hsv抗体的局部应用
AU2016342049B2 (en) * 2015-10-22 2023-05-18 Modernatx, Inc. Herpes simplex virus vaccine
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
BR112019014406A2 (pt) * 2017-01-20 2020-04-28 Atara Biotherapeutics Inc métodos de tratar esclerose múltipla usando células t autólogas
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
EP4196134A1 (en) * 2020-08-13 2023-06-21 Rootpath Genomics, Inc. Compositions and methods for antigen identification
WO2022212289A1 (en) * 2021-03-29 2022-10-06 Rational Vaccines, Inc. Mutant herpesvirus and vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
EP0541692B1 (en) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
CA2270282A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
CA2291010A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
EP1064390A4 (en) * 1998-03-20 2002-06-12 Genzyme Corp Enhanced anti-tumor immunity

Also Published As

Publication number Publication date
JP2012214478A (ja) 2012-11-08
NZ517959A (en) 2004-05-28
PL355265A1 (en) 2004-04-05
TR200200838T2 (tr) 2002-06-21
CN1376201A (zh) 2002-10-23
EP1222281B1 (en) 2006-11-15
CA2379623C (en) 2014-09-09
EP1222281A2 (en) 2002-07-17
JP5602188B2 (ja) 2014-10-08
AU2005234654B2 (en) 2008-04-24
AU782676B2 (en) 2005-08-18
CA2379623A1 (en) 2001-04-05
US6413518B1 (en) 2002-07-02
HK1044799A1 (zh) 2002-11-01
WO2001023414A3 (en) 2001-11-08
WO2001023414B1 (en) 2002-02-28
DE60031874D1 (de) 2006-12-28
KR20020048944A (ko) 2002-06-24
US20020155122A1 (en) 2002-10-24
JP2003512305A (ja) 2003-04-02
AU2005234654A1 (en) 2005-12-15
ATE345389T1 (de) 2006-12-15
NO20021479D0 (no) 2002-03-25
NZ531980A (en) 2005-04-29
WO2001023414A2 (en) 2001-04-05
NO20021479L (no) 2002-05-03
US6962709B2 (en) 2005-11-08
AU7836400A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
BR0014408A (pt) Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
BR9912671A (pt) Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
LU93101I2 (fr) Imlygic-talimogene laherparepvec
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
EP2316479B8 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
MX2023012368A (es) Vacuna de virus.
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
GB2359083A (en) Mutant herpes simplex viruses and uses thereof
BR0012985A (pt) Vacina, bactéria, uso da mesma, e composição farmacêutica e métodos de tratamento ou prevenção de doença mediada por hsv em um hospedeiro humano ou animal e de uma infecção viral da mucosa de um hospedeiro humano ou animal

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]